论文部分内容阅读
目的:评价新药卡维地洛片治疗轻、中度原发性高血压的降压疗效和安全性。方法:25例轻、中度高血压病患者经过2周清洗期后,服卡维地洛片10mg bid;治疗2周后其中血压下降不满意者9例(舒张压>90mmHg)增加剂量为20mg bid,共观察4周。结果:服药后第1周末舒张压即明显下降,治疗第3周后收缩压也显著下降。4周降压治疗总有效率为88％,服卡维地洛20mg/d、40mg/d的总效率分别为56％、32％。用药前后心率无明显变化,血清总胆固醇、甘油三酯均无明显变化。服卡维地洛后高密度脂蛋白胆固醇虽明显下降,但仍在正常范围内。不良反应少而轻。结论:卡维地洛治疗轻、中度高血压有效、安全,值得临床推广使用。
Objective: To evaluate the antihypertensive effect and safety of the new drug carvedilol tablet in the treatment of mild to moderate essential hypertension. Methods: Twenty-five patients with mild and moderate essential hypertension were treated with carvedilol 10mg bid after 2 weeks washout period. After 2 weeks of treatment, 9 patients (diastolic blood pressure> 90mmHg) bid, observed a total of 4 weeks. Results: The diastolic blood pressure decreased markedly on the first weekend after taking the medicine, and the systolic blood pressure decreased significantly after the third week of treatment. The total effective rate of 4-week antihypertensive treatment was 88%, and the total efficiency of carvedilol 20mg / d and 40mg / d was 56% and 32% respectively. No significant changes in heart rate before and after treatment, serum total cholesterol, triglycerides were no significant changes. After serving carvedilol high density lipoprotein cholesterol, although significantly decreased, but still within the normal range. Adverse reactions and less. Conclusion: Carvedilol is effective and safe for light and moderate hypertension and is worthy of clinical promotion.